Vitreous substitutes

SSSIHMS-PG
SSSIHMS-PGSSSIHMS-PG
VITREOUS
SUBSTITUTES
DR PAVANKUMAR NAIK
Anatomy of vitreous1
• Gelatinous structure that
fills the space between lens
and retina
• Non homogenous
• Vitreous cortex
• Vitreous base
• Vitreo retinal interface
• 99% water (vol-4ml)
• Proteins 200 to 1400 mg/ml
• Collagens-II(60-75%) ,IX,VI
300 ug/ml
• GAGs-hyaluronic acid, 65-
400 mg/ml chondroitin
sulfate, heparan sulfate
• Ascorbic acid
• Amino acids
• Fatty acids
• Cells –hyalocytes, fibrocytes,
macrophages
When to substitute?
• > 2 ml vitreous removed
• Major vitreo retinal surgeries
Ideal Vitreous Substitute3
Form
ManipulatableFunction
• VISCOELASTIC
• ALLOW MOVEMENT OF IONS AND ELECTROLYTES
• OPTICALLY CLEAR
• ONE TIME IMPLANTATION
• SELF RENEWABLE
• NON TOXIC, BIOCOMPATIBLE, NON
BIODEGRADABLE
• READILY AVAILABLE, REASONABLE COST AND
STORAGE
Classification2
Classification Example
Aqueous miscible
Low viscosity Balanced salt solution
High viscosity Chondroitin sulfate
Viscoelastic Hyaluronic acid, hydroxymethylcellulose
Aqueous immiscible Gases
Air, sulfur hexafluoride (SF6),
perfluoropropane (C3F8)
Liquids
Lighter than aqueous Silicone oil
Heavier than aqueous Perfluorocarbon liquids, Semiflourinated
alkanes,
Fluorinated silicone oil
Experimental Vitreous substitutes4
a) Polymers
• Hydrogels
• Smart hydrogels
• Thermosetting gels
b) Implants
c) Cell culture
Intra-Ocular
Gases2,3,9
• 1911 by Ohm.
• Rosengren used intravitreal air injection with drainage of
subretinal fluid and diathermy
• 1973, Norton used sulfur hexafluoride (SF6) gas for a longer
tamponade >air used for difficult retinal detachments,
particularly giant tears.
• Lincoff and associates then developed several perfluorocarbon
gases
Non
Expanding
AIR
XENON
Expanding
SF6
PFC
• SURFACE TENSION
• BUOYANCY
• SOLUBILITY
• BIOCOMPATIBILITY
• Surface tension –
between gas bubbles
and surrounding fluids
critical physical
property
of the gases in retinal
reattachment
• Electrostatic attractive
forces -van der Waals
forces -weaker and
longer range
• Buoyancy-ability to float
• Due to large difference in
specific gravity of fluid
and gas
• superior tear tamponaded
with a large air bubble
• Displaces fluid inferiorly
and away from the tear
• Flattens against the wall
of the eye.
• Buoyancy directs the
effectiveness of the
tamponade, gases -upward
gravitational direction.
• Large bubbles and face-
down positioning are
required to tamponade
inferior retinal breaks
apposition of the gas bubble against the
posterior pole and macula during face
down positioning.
• Solubility of a gas in the aqueous medium :
determining the reabsorption rate of a gas bubble
from the vitreous cavity
• If less soluble than nitrogen, expansion of the bubble
can occur
Biocompatibility
• SF6 and the perfluorocarbon gases have a purity of
99.8%
• Pure gases -chemically nonreactive, colorless,
odorless, and nontoxic
• SF6 may -0.3 ppm of hydrogen fluoride. regarded as
the most toxic contaminant found in SF6.
• When bubble is large enough , covers the back of the lens, a
cataract develops unless the patient is positioned so that a
layer of fluid covers the posterior surface of the lens
• On contact with corneal endothelium -causes increased
inflammation, >SF6 than perfluoropropane
• Persistent corneal edema and retro- corneal membrane -
interference with nutrition of the endothelium rather than to a
specific toxic effect
Gas Dynamics
• Bubble Expansion-gas from surrounding fluid
enter the bubble
• Equilibrium with N2: partial pressures of both
compartments equilibrate: o2/co2 diffuse rapidly, N2
slowly, maximum in 6-8 hours
• Bubble dissolution: as gases diffuse out bubble
decreases in size
Role of Gas bubble
• Bubble larger than the break-surface tension of gas prevents it
from passing through the retinal break
• Gas bubble apposed to the posterior end of break
• Passage of fluid from the vitreous to SRF blocked
• SRF absorbed into RPE and choroid
• Sp gravity of gas lower than water
• Buoyant forces push retina against RPE (max at apex ) 10x >
silicone oil)
• Head position till chorio- retinal adhesion
Advantages:
• When visualisation of retina is difficult-optical window
• Allows fluid gas exchange
• Mechanical barrier-cellular elements & growth factors
“compartmentalisation”
0.3-0.5ml injected
rapidly into the eye to
avoid “fish egg bubble
“formation
Factors affecting dissolution
• Vitreous currents
• Surface area of bubble
• Gas solubility in fluid
• Diffusion coefficient of gas
• Partial pressures
• Ocular blood flow
Vitreous substitutes
CHANGES IN THE VITREOUS
• In a non vitrectomised eye: collagen condensed and
compacted behind lens and at optic nerve head
• Hyaluronic acid expressed from vitreous space
• Lamellae - concave margins and rolled edges
• ? Formation of pre retinal membranes complicating
retinal detachment
Choice of Gas
Condition Xenon Air SF6 C2F6 C3F8
RD 2 1 1 2 --
PDR -- 1 1 2 --
RD+mac
hole
-- 2 1 -- 2
GRT -- 1 1 -- 2
PVR -- -- -- -- 1
Trauma -- 2 1 1 2
1-mc used 2-
selected cases
• Inj using 30 g , 13 mm needle
• Injected immediately
• Head position during air fluid exchange
Complications of gas use
• Cataract or corneal opacity
-Face-down or lateral positioning is necessary to
prevent continuous contact of the gas bubble with the
cornea and lens
• Glaucoma
-large bubble
-if the patient remains supine, fluid from the ciliary
body fills the posterior segment & air bubble blocks
fluid egress through the trabecular meshwork
-Medium size -peripheral anterior synechiae with total
angle closure
• Central Retinal Artery Occlusion
-Overfilling of the eye with expansile gas
• Laser treatment -undesirable burns
-Reflections of internal fluid–air and air–fluid surfaces.
-Avoid treatment through a gas–fluid or fluid–gas
interface
-Perpendicular to the interface: intensity of a reflected
beam increases as the angle of incidence decreases. -A
divergent beam should be used
• Endophthalmitis
• Subretinal gas
• New tears -7% to 23% of patients treated with
pneumatic retinopexy
• Dislocated intraocular lens implant
Gas injection into
vitreous base accidentally
A. Donut sign when gas
encircles the lens
posteriorly.
B. B. Sausage sign when
gas partially encircles
the lens posteriorly.
In both cases the gas
bubble is immobile
Perfluoro-
carbons2,10
• Fluorine and carbon atoms - most biologically inert in the eye
• Surface tension of approximately 14 to 16 dynes/cm measured
against air –comparable to silicone oil
• Most remarkable property of the perfluorocarbon liquids is the
specific gravity, which is higher than that of water.
• specific gravities range from 1.7 to 2.03
• Enables the fluid to settle posteriorly, opening folds in the
retina while expressing subretinal fluid anteriorly through pre-
existing retinal breaks
• Perfluorodecalin & perfluorophenanthrene -high transparency
to light in the visible spectrum
• No obstacle to laser photocoagulation
• Perfluorooctylbromide is radiopaque, and it has potential
application as a contrast agent
Biocompatibility
• Inferior corneal endothelial loss with subsequent corneal opacity and
thickening
• Dispersion and droplet formation will develop
• Gial cell proliferation and retinal disorganization -1 month.
• 3 months-preretinal membranes, gliosis, and retinal disorganization
• 6 months, retinal detachments
• Perfluorotributylamine -a “moth-eaten appearance,” - irregularly
shaped defects in the outer segment discs in both the superior and
the inferior retina after 2 days
• Combined use of silicone oil and perfluoropolyether has shown a
tendency to reduce the emulsification PFC
5 main indications:
• Giant retinal tears
• Detachments with complicated PVR
• Traumatic retinal detachments
• Removal of posterior lens fragments and posteriorly dislocated
intraocular lenses
• Macular rotation with a 360-degree retinotomy
• +ROP
• PVR: tamponade effect to
open up funnel detachment
exposing any areas of
residual membranes
• Giant retinal tears:
unfolding and displacement
of SRF and blood
• PPV removal of anterior
vitreous base
• Crystalline lens floated
anteriorly over ONH
• SRF displaced through
the break
• Posterior retina flattened
• Dislocated lens removed
with fragmatome/vit
cutter
DISADVANTAGES
• irreversible cell damage
• Disorganization of retinal
cell growth pattern, loss of
neurites
ADVANTAGES
• Specific gravity of PFCLs -
effective for the intraoperative
repair of complex retinal tears
• Anterior and posterior segment
complications are uncommon
• Low viscosity of PFCLs allow
for tissue manipulation,
injection, and removal
SemiFluorinated
Alkanes2
• Semifluorinated alkanes (SFAs),or partially fluorinated
alkanes (PFAs) or FA -first internal tamponade agents - used
beyond the intraoperative setting
• Low sp. gravity of SFA< PFCLs:so produce less retinal
damage
• Esp used for macular rotation surgery -press down on the
retina less , allowing rotation of the unfolded macular without
mechanical damage
• Using F6H8 and OL62 HV oligomers increases viscosity and
decreases droplet formation
• Ex: Perfluorohexyloctane(F6H8/O68),
Perfluorohexylethane(F6H2/O62)
• Complications: Glaucoma-Superior PI, Cataract ,Droplet
formation & dispersion
Silicone Oil2,10
• Silicone oil chains - helix
with six silicium units per
turn.
• Pure 1,000-centistoke oil -
helix of 63 turns and a
5,000-centistoke oil a
helix of approximately
100 turns
• Interdigitation of the helix
& increasing molecular
weight -viscosity
linear chain coils into a helix,
composed of 6 (Si-O) units per turn.
For a molecular weight of 28,000
(1,000 centistokes), the helix will
have 63 turns in average
• Buoyancy:
• Difference in specific gravity of aqueous humor, vitreous and
hydrophobic polymer accounts for buoyancy
• Force is spread over an area max at apex and decreases to zero
at horizontal interface
• Directs the tamponade of the immiscible silicone oil upward.
Refractive state of the eye
• Higher refractive index compared to vitreous
• Refractive shift depends on lens status
• Phakic eye-oil forms a concave surface behind lens
Acts as a minus lens-making eye hyperopic-8D hyperopia
• Aphakic eye-convex surface as it bulges through pupillary
aperture-plus lens-myopic
Varies with pupillary aperture size-from +12.5 to +5.6D
• Contact lens –to minimise the anisoconia
• IOL-plano posterior surface preferred
Vitreous substitutes
Indications for silicone oil
B. Severe Proliferative Diabetic Retinopathy
• Silicone oil: decreased post op hemorrhage
• Rapid recovery
• Especially in patients with anterior segment
neovascularisation/anterior hyaloid proliferation
• Acts by impending movement of vasoproliferative factors
from posterior segment to anterior segment
• PDR with rhegmatogenous RD involving the macula
C. Macular Hole
• RD due to macular hole
• Idiopathic/Traumatic macular hole
D. Giant Retinal Tears
• Unfolding the tear
• Long term tamponade
E. Chronic uveitis with profound hypotony
F. Infectious retinitis
• RRD in CMV retinitis
• Gancyclovir implants with silicone tamponade
F. Endophthalmitis
• Increase concentration of intravitreal antibioticcs
• Antibacterial properties of silicone oil
• Stabilise atrophic retina
Complications of Silicone
Oil
• Cataract,
• Glaucoma,
• Keratopathy
• Absorption of silicone oil by silicone intraocular lenses,
• Migration of silicone oil into the optic nerve and rarely into the
brain, and
• Emulsification.
• Retinopathy
• Recurrent retinal detachments
Vitreous substitutes
Emulsification of Silicone
Oils
• Smaller silicone oil droplets at the interface of oil droplet and intra
ocular fluids
• Factors promoting emulsification:
-Difference in density of two liquids
-Lower viscosity
-Decrease in interfacial tension
-Adsorption of surface active agents
-Ocular saccadic motion
(micro current in and outside the bubble)
1%-1month, 11%-3 months ,85% 6 months, 100%- 1 year 8
Stages of Emulsification
• Choice of IOL: heparin coated PMMA/ regular PMMA
• Silicone oil acts as a foreign substance and not reabsorbed by
the eye
• On removal-retinal redetachment 3-33%
• Indications for removal:
-Glaucoma
-Keratopathy
-reasonable chance that retina will remain attached
(followed by infusion of BSS / Air –fluid exchange)
Vitreous substitutes
• Disadvantages
• can pass through retinal
breaks under traction
• Requires optical
adjustments
• tamponade of the inferior
retina is difficult
• Emulsification
• Complications
• Sticky silicone oil
o Advantages
• high surface tension, ease of
removal, low toxicity, and
transparency.
• tamponade effect on the
superior retina
• airplane or high elevation
travel is planned
• post-operative positioning is
difficult
• Combinations
“Double Fill”
• Double fill (DF) is a combination of SO and SFAs,
• light SO support the superior retina ,heavier SFA supports the
inferior retina,
• Tamponade agent and reduces dispersion
“Heavy Silicone Oil”
• SO and a PFA mixed in such a way as to create a homogenous
solution.
• More viscous, more stable
• Complex retinal detachments involving inferior proliferative
vitreoretinopathy
• HSO can be challenging to remove-heavier than water
Experimental
substitutes 3
vitreous molecular
structure
filling function,
to control
elasticity
pressure of the
eye
chemical and
physiological
properties
diffusion of
metabolites
and gases
Perfusion of
drugs
Interact with
intraocular
structures
A Natural Polymers
• Hyaluronic acid (HA) and collagen,
B Hydrogels “swell gels”
• hydrophilic polymers that form a gel network when cross-
linked & swell by absorbing several times their own weight in
water
• molecules as tamponades is coupled with the active action as
drug releasers or exchangers
• investigated include poly(vinyl alcohol),poly(1-vinyl-2-
pyrrolidone), poly(acrylamide), copoly(acrylamide), polyvinyl
alcohol methacrylate, poly(glyceryl methacrylate), poly(2-
hydroxythylacrylate), and poly(methyl-2-acrylamido-2-
methoxyacetate).
C. Transplants & Implants
• Transplant vitreal tissue
• Correctly stored, the vitreous body :maintain its structure
and also its enzymatic properties
• Low inflammatory reaction and interesting surgical
results on 40% of patients.
• Cataract, glaucoma, and more severe adverse events until
ocular atrophy
.
Implants
• artificial capsular bodies,
• silicone rubber elastomer and filled with a saline solution,
• silicone oil, controlled using a valve system
• FCVB
• Good mechanical, optical, and biocompatible properties
• PVA filling model
• X. Lin, J. Ge, Q. Gao et al., “Evaluation of the flexibility,
efficacy,and safety of a foldable capsular vitreous body in the
treatment of severe retinal detachment,” Investigative
Ophthalmology &Visual Science, vol. 52, no. 1, pp. 374–381, 2011.
Future??
A. VITREOUS SUBSTITUTES AS A DRUG DELIVERY
MEDIUM
• A proper vitreous substitute used as a long-term (>3
months) drug delivery system to reduce or eliminate the
need for multiple intra-vitreal injections
• Hydrogels may be a promising biomaterial for fragile
protein drug delivery
B. CELL CULTURE/GENE THERAPY: CAN WE GROW
VITREOUS?
REFERENCES
1. SURVEY OF OPHTHALMOLOGY VOLUME 56 NUMBER 4 JULY–AUGUST 2011
Vitreous Substitutes: A Comprehensive Review Teri T. Kleinberg, MS, MD,1 Radouil T.
Tzekov, MD, PhD,1 Linda Stein, MS,1 Nathan Ravi, MD, PhD,2 and Shalesh Kaushal,
MD, PhD1
2. Duanes Ophthalmology Volume 6 ,Chapter 54 Vitreous Substitutes MARK E.
HAMMER
3.Hindawi Publishing Corporation BioMed Research InternationalVolume 2014,
Article ID 351804, 12 pagesReview Article Vitreous Substitutes: The Present and the
Future Simone Donati,1 Simona Maria Caprani,1 Giulia Airaghi,1 Riccardo
Vinciguerra,1 Luigi Bartalena,2 Francesco Testa,3 Cesare Mariotti,4 Giovanni Porta,5
Francesca Simonelli,3 and Claudio Azzolini1
4.Intraocular gas in vitreoretinal Surgery Shaheeda Mohamed, FRCS, Timothy Y. Y.
Lai, MD, FRCS
5.Department of Ophthalmology & Visual Sciences, The Chinese University of Hong
Kong, Hong Kong
5.Department of Ophthalmology & Visual Sciences, The Chinese University of
Hong Kong, Hong Kong
6.Swartz M, Anderson DR: Use of Healon in posterior segment surgery. J Ocul Ther
Surg , January-February, pp 26–28, 1984
7.Poole TA, Sudarsky RD: Suprachoroidal implantation for the treatment of retinal
detachment. Ophthalmology 93:1408, 1986
8.Stenkula S, Ivert L, Gislason I, et al: The use of sodiumhyaluronate (Healon) in the
treatment of retinal detachment. Ophthalmic Surg 12:435, 1981
9.Stenkula S: Sodium hyaluronate as a vitreous substitute and intravitreal surgical
tool. In Rosen ES (ed): Viscoelastic Materials: Basic Science and Clinical
Applications, pp 157–160. New York, Pergamon Press, 1989
10.Stephen J Ryan –Retina 4 th edition volume 3
11.Lincoff H, Mardirossian J, Lincoff A, et al: Intravitreal longevity of three
perfluorocarbon gases. Arch Ophthalmol 98:1610, 1980
12.Silicone Study Group: Vitrectomy with silicone oil or perfluoropropane gas in eyes
with severe proliferative vitreoretinopathy: Results of a randomized clinical trial: Report
2 Arch Ophthalmol 110:780, 1992
1 sur 68

Recommandé

Vitreous substitutes par
Vitreous substitutesVitreous substitutes
Vitreous substitutessri kiran eye institue
4K vues69 diapositives
Anophthalmic socket par
Anophthalmic socketAnophthalmic socket
Anophthalmic socketSivateja Challa
11.8K vues49 diapositives
Diagnosis of pre perimetric glaucoma par
Diagnosis of pre perimetric glaucomaDiagnosis of pre perimetric glaucoma
Diagnosis of pre perimetric glaucomaSadhwini Harish
5.9K vues73 diapositives
Choroidal detachment par
Choroidal detachmentChoroidal detachment
Choroidal detachmentSSSIHMS-PG
13.2K vues48 diapositives
Vitreous Substitutes - Dr Shylesh B Dabke par
Vitreous Substitutes - Dr Shylesh B DabkeVitreous Substitutes - Dr Shylesh B Dabke
Vitreous Substitutes - Dr Shylesh B DabkeShylesh Dabke
4K vues52 diapositives
Macular hole par
Macular holeMacular hole
Macular holeDr Samarth Mishra
14.9K vues42 diapositives

Contenu connexe

Tendances

Anterior segment OCT & UBM par
Anterior segment OCT & UBMAnterior segment OCT & UBM
Anterior segment OCT & UBMDinesh Madduri
12.4K vues84 diapositives
Diabetic retinopathy Trials par
Diabetic retinopathy TrialsDiabetic retinopathy Trials
Diabetic retinopathy TrialsKaran Bhatia
12.8K vues52 diapositives
Multifocal iols par
Multifocal iolsMultifocal iols
Multifocal iolsSSSIHMS-PG
16K vues48 diapositives
AS-OCT par
AS-OCTAS-OCT
AS-OCTSwetha Ravichandran
4.2K vues67 diapositives
Complications of cataract surgery par
Complications of cataract surgeryComplications of cataract surgery
Complications of cataract surgeryDr Laltanpuia Chhangte
22K vues84 diapositives
Choroidal neovascularisation(cnv) par
Choroidal neovascularisation(cnv)Choroidal neovascularisation(cnv)
Choroidal neovascularisation(cnv)Nikhil Rp
7.4K vues83 diapositives

Tendances(20)

Diabetic retinopathy Trials par Karan Bhatia
Diabetic retinopathy TrialsDiabetic retinopathy Trials
Diabetic retinopathy Trials
Karan Bhatia12.8K vues
Choroidal neovascularisation(cnv) par Nikhil Rp
Choroidal neovascularisation(cnv)Choroidal neovascularisation(cnv)
Choroidal neovascularisation(cnv)
Nikhil Rp7.4K vues
AC/A par zarin45
AC/AAC/A
AC/A
zarin4538.1K vues
Proliferative vitreoretinopathy par PavanShroff
Proliferative vitreoretinopathyProliferative vitreoretinopathy
Proliferative vitreoretinopathy
PavanShroff6.4K vues
Yag capsulotomy par Rohit Rao
Yag capsulotomyYag capsulotomy
Yag capsulotomy
Rohit Rao9.9K vues
Choroidal neovascular membranes (CNVM) par Md Riyaj Ali
Choroidal neovascular membranes (CNVM)Choroidal neovascular membranes (CNVM)
Choroidal neovascular membranes (CNVM)
Md Riyaj Ali2.1K vues
Vitreous substitutes in ophthalmology par mdalbanuddin
 Vitreous substitutes in ophthalmology Vitreous substitutes in ophthalmology
Vitreous substitutes in ophthalmology
mdalbanuddin395 vues
Branch retinal vein occlusion (BRVO) par NIKHIL GOTMARE
Branch retinal vein occlusion (BRVO)Branch retinal vein occlusion (BRVO)
Branch retinal vein occlusion (BRVO)
NIKHIL GOTMARE6.5K vues
Pigment epithelial detachment (PED) par Md Riyaj Ali
Pigment epithelial detachment (PED)Pigment epithelial detachment (PED)
Pigment epithelial detachment (PED)
Md Riyaj Ali1.7K vues
Scleral buckling for rhegmatogenous retinal detachment par reboca smith
Scleral buckling for rhegmatogenous retinal detachmentScleral buckling for rhegmatogenous retinal detachment
Scleral buckling for rhegmatogenous retinal detachment
reboca smith4.2K vues

Similaire à Vitreous substitutes

Final seminar par
Final seminarFinal seminar
Final seminarMahrukh Khan
145 vues24 diapositives
CORNEAL PHYSIOLOGY in relation to contact lens par
CORNEAL PHYSIOLOGY in relation to contact lens CORNEAL PHYSIOLOGY in relation to contact lens
CORNEAL PHYSIOLOGY in relation to contact lens Manisha Dahal
5.2K vues109 diapositives
Corneal opacity 2.pptx par
Corneal opacity 2.pptxCorneal opacity 2.pptx
Corneal opacity 2.pptxAnsifK2
10 vues16 diapositives
Physiology of the cornea par
Physiology of the corneaPhysiology of the cornea
Physiology of the corneaDesta Genete
581 vues68 diapositives
Corneal collagen cross linking par
Corneal collagen cross linkingCorneal collagen cross linking
Corneal collagen cross linkingPaavan Kalra
19.1K vues53 diapositives

Similaire à Vitreous substitutes(20)

CORNEAL PHYSIOLOGY in relation to contact lens par Manisha Dahal
CORNEAL PHYSIOLOGY in relation to contact lens CORNEAL PHYSIOLOGY in relation to contact lens
CORNEAL PHYSIOLOGY in relation to contact lens
Manisha Dahal5.2K vues
Corneal opacity 2.pptx par AnsifK2
Corneal opacity 2.pptxCorneal opacity 2.pptx
Corneal opacity 2.pptx
AnsifK210 vues
Corneal collagen cross linking par Paavan Kalra
Corneal collagen cross linkingCorneal collagen cross linking
Corneal collagen cross linking
Paavan Kalra19.1K vues
Lacrimal system ii,03.08.2016, a.r.rajalakshmi par Srikanth K
Lacrimal system ii,03.08.2016, a.r.rajalakshmiLacrimal system ii,03.08.2016, a.r.rajalakshmi
Lacrimal system ii,03.08.2016, a.r.rajalakshmi
Srikanth K385 vues
ContactLensComplications[1].ppt par mikaelgirum
ContactLensComplications[1].pptContactLensComplications[1].ppt
ContactLensComplications[1].ppt
mikaelgirum7 vues
Laser BASED PROCEDURES par Mahrukh Khan
Laser BASED PROCEDURES Laser BASED PROCEDURES
Laser BASED PROCEDURES
Mahrukh Khan111 vues
Corneal transparency par Tina Chandar
Corneal transparencyCorneal transparency
Corneal transparency
Tina Chandar34.2K vues
Diagnosis & management of dry eye par SUCHETAMITRA2
Diagnosis & management of dry eyeDiagnosis & management of dry eye
Diagnosis & management of dry eye
SUCHETAMITRA21.6K vues
Dr. r.subramaniyan, 08 3-17 tear film par ophthalmgmcri
Dr. r.subramaniyan, 08 3-17 tear filmDr. r.subramaniyan, 08 3-17 tear film
Dr. r.subramaniyan, 08 3-17 tear film
ophthalmgmcri4.4K vues
Dr. reema thomas 12 1-17 tear film par ophthalmgmcri
Dr. reema thomas 12 1-17 tear filmDr. reema thomas 12 1-17 tear film
Dr. reema thomas 12 1-17 tear film
ophthalmgmcri398 vues
IOL IN CATARACT SURGERY.pptx par Dshri Sankar
IOL IN CATARACT SURGERY.pptxIOL IN CATARACT SURGERY.pptx
IOL IN CATARACT SURGERY.pptx
Dshri Sankar394 vues
Rhegmatogenous Retinal Detachment --RRD par Nana Tsertsvadze
 Rhegmatogenous  Retinal  Detachment --RRD Rhegmatogenous  Retinal  Detachment --RRD
Rhegmatogenous Retinal Detachment --RRD
Nana Tsertsvadze2.7K vues
Contact lens in keratoconus 2 par Atif Rahman
Contact lens in keratoconus 2Contact lens in keratoconus 2
Contact lens in keratoconus 2
Atif Rahman3K vues

Plus de SSSIHMS-PG

Duanes retraction syndrome .. par
Duanes retraction syndrome ..Duanes retraction syndrome ..
Duanes retraction syndrome ..SSSIHMS-PG
18.4K vues53 diapositives
Visual evoked potential par
Visual evoked potentialVisual evoked potential
Visual evoked potentialSSSIHMS-PG
36K vues40 diapositives
Iridocorneal endothelial syndrome par
Iridocorneal endothelial syndromeIridocorneal endothelial syndrome
Iridocorneal endothelial syndromeSSSIHMS-PG
10.4K vues34 diapositives
Optic neuritis par
Optic neuritisOptic neuritis
Optic neuritisSSSIHMS-PG
32.7K vues37 diapositives
Supranuclear disorders of ocular motility par
Supranuclear disorders of ocular motilitySupranuclear disorders of ocular motility
Supranuclear disorders of ocular motilitySSSIHMS-PG
6.5K vues49 diapositives
Anatomy and physiology of cornea par
Anatomy and physiology of corneaAnatomy and physiology of cornea
Anatomy and physiology of corneaSSSIHMS-PG
30.3K vues59 diapositives

Plus de SSSIHMS-PG(20)

Duanes retraction syndrome .. par SSSIHMS-PG
Duanes retraction syndrome ..Duanes retraction syndrome ..
Duanes retraction syndrome ..
SSSIHMS-PG18.4K vues
Visual evoked potential par SSSIHMS-PG
Visual evoked potentialVisual evoked potential
Visual evoked potential
SSSIHMS-PG36K vues
Iridocorneal endothelial syndrome par SSSIHMS-PG
Iridocorneal endothelial syndromeIridocorneal endothelial syndrome
Iridocorneal endothelial syndrome
SSSIHMS-PG10.4K vues
Optic neuritis par SSSIHMS-PG
Optic neuritisOptic neuritis
Optic neuritis
SSSIHMS-PG32.7K vues
Supranuclear disorders of ocular motility par SSSIHMS-PG
Supranuclear disorders of ocular motilitySupranuclear disorders of ocular motility
Supranuclear disorders of ocular motility
SSSIHMS-PG6.5K vues
Anatomy and physiology of cornea par SSSIHMS-PG
Anatomy and physiology of corneaAnatomy and physiology of cornea
Anatomy and physiology of cornea
SSSIHMS-PG30.3K vues
Congenital glaucomas par SSSIHMS-PG
Congenital glaucomasCongenital glaucomas
Congenital glaucomas
SSSIHMS-PG6.1K vues
neovascular glaucoma par SSSIHMS-PG
neovascular glaucomaneovascular glaucoma
neovascular glaucoma
SSSIHMS-PG12.4K vues
Optics of ametropia par SSSIHMS-PG
Optics of ametropiaOptics of ametropia
Optics of ametropia
SSSIHMS-PG13.2K vues
Miotics and mydriatics par SSSIHMS-PG
Miotics and mydriaticsMiotics and mydriatics
Miotics and mydriatics
SSSIHMS-PG100K vues
Refraction using a phoropter par SSSIHMS-PG
Refraction using a phoropterRefraction using a phoropter
Refraction using a phoropter
SSSIHMS-PG31.9K vues
Slit lamp biomicroscopy par SSSIHMS-PG
Slit lamp biomicroscopySlit lamp biomicroscopy
Slit lamp biomicroscopy
SSSIHMS-PG7.9K vues
Uveitic glaucoma par SSSIHMS-PG
Uveitic glaucomaUveitic glaucoma
Uveitic glaucoma
SSSIHMS-PG4.3K vues
Complications of squint sx par SSSIHMS-PG
Complications of squint sxComplications of squint sx
Complications of squint sx
SSSIHMS-PG4.1K vues
HRT and GDx VCC par SSSIHMS-PG
HRT and GDx VCCHRT and GDx VCC
HRT and GDx VCC
SSSIHMS-PG11.7K vues
Vitreomacular traction par SSSIHMS-PG
Vitreomacular tractionVitreomacular traction
Vitreomacular traction
SSSIHMS-PG5.7K vues
Angle recession glaucoma par SSSIHMS-PG
Angle recession glaucomaAngle recession glaucoma
Angle recession glaucoma
SSSIHMS-PG13.9K vues
Hvf progession par SSSIHMS-PG
Hvf progessionHvf progession
Hvf progession
SSSIHMS-PG1.8K vues
Pigment dispersion syndrome par SSSIHMS-PG
Pigment dispersion syndromePigment dispersion syndrome
Pigment dispersion syndrome
SSSIHMS-PG11.5K vues

Dernier

Structural Racism and Public Health: How to Talk to Policymakers and Communit... par
Structural Racism and Public Health: How to Talk to Policymakers and Communit...Structural Racism and Public Health: How to Talk to Policymakers and Communit...
Structural Racism and Public Health: How to Talk to Policymakers and Communit...katiequigley33
912 vues31 diapositives
Depression PPT template par
Depression PPT templateDepression PPT template
Depression PPT templateEmanMegahed6
20 vues36 diapositives
Asthalin Inhaler (Generic Albuterol Sulfate Inhaler) par
Asthalin Inhaler (Generic Albuterol Sulfate Inhaler) Asthalin Inhaler (Generic Albuterol Sulfate Inhaler)
Asthalin Inhaler (Generic Albuterol Sulfate Inhaler) The Swiss Pharmacy
6 vues20 diapositives
NMP-9.pptx par
NMP-9.pptxNMP-9.pptx
NMP-9.pptxSai Sailesh Kumar Goothy
23 vues46 diapositives
Cholera Romy W. (3).pptx par
Cholera Romy W. (3).pptxCholera Romy W. (3).pptx
Cholera Romy W. (3).pptxrweth613
53 vues11 diapositives
CRANIAL NERVE EXAMINATION.pptx par
CRANIAL NERVE EXAMINATION.pptxCRANIAL NERVE EXAMINATION.pptx
CRANIAL NERVE EXAMINATION.pptxNerusu sai priyanka
184 vues30 diapositives

Dernier(20)

Structural Racism and Public Health: How to Talk to Policymakers and Communit... par katiequigley33
Structural Racism and Public Health: How to Talk to Policymakers and Communit...Structural Racism and Public Health: How to Talk to Policymakers and Communit...
Structural Racism and Public Health: How to Talk to Policymakers and Communit...
katiequigley33912 vues
Asthalin Inhaler (Generic Albuterol Sulfate Inhaler) par The Swiss Pharmacy
Asthalin Inhaler (Generic Albuterol Sulfate Inhaler) Asthalin Inhaler (Generic Albuterol Sulfate Inhaler)
Asthalin Inhaler (Generic Albuterol Sulfate Inhaler)
Cholera Romy W. (3).pptx par rweth613
Cholera Romy W. (3).pptxCholera Romy W. (3).pptx
Cholera Romy W. (3).pptx
rweth61353 vues
Peptic ulcer.pdf par UVAS
Peptic ulcer.pdfPeptic ulcer.pdf
Peptic ulcer.pdf
UVAS9 vues
VarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective par Golden Helix
VarSeq 2.5.0: VSClinical AMP Workflow from the User PerspectiveVarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective
VarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective
Golden Helix83 vues
Complications & Solutions in Laparoscopic Hernia Surgery.pptx par Varunraju9
Complications & Solutions in Laparoscopic Hernia Surgery.pptxComplications & Solutions in Laparoscopic Hernia Surgery.pptx
Complications & Solutions in Laparoscopic Hernia Surgery.pptx
Varunraju9126 vues
PATIENTCOUNSELLING in.pptx par skShashi1
PATIENTCOUNSELLING  in.pptxPATIENTCOUNSELLING  in.pptx
PATIENTCOUNSELLING in.pptx
skShashi121 vues
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends par muskansbl01
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness TrendsTop Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends
muskansbl0141 vues

Vitreous substitutes

  • 2. Anatomy of vitreous1 • Gelatinous structure that fills the space between lens and retina • Non homogenous • Vitreous cortex • Vitreous base • Vitreo retinal interface
  • 3. • 99% water (vol-4ml) • Proteins 200 to 1400 mg/ml • Collagens-II(60-75%) ,IX,VI 300 ug/ml • GAGs-hyaluronic acid, 65- 400 mg/ml chondroitin sulfate, heparan sulfate • Ascorbic acid • Amino acids • Fatty acids • Cells –hyalocytes, fibrocytes, macrophages
  • 4. When to substitute? • > 2 ml vitreous removed • Major vitreo retinal surgeries
  • 6. • VISCOELASTIC • ALLOW MOVEMENT OF IONS AND ELECTROLYTES • OPTICALLY CLEAR • ONE TIME IMPLANTATION • SELF RENEWABLE • NON TOXIC, BIOCOMPATIBLE, NON BIODEGRADABLE • READILY AVAILABLE, REASONABLE COST AND STORAGE
  • 7. Classification2 Classification Example Aqueous miscible Low viscosity Balanced salt solution High viscosity Chondroitin sulfate Viscoelastic Hyaluronic acid, hydroxymethylcellulose Aqueous immiscible Gases Air, sulfur hexafluoride (SF6), perfluoropropane (C3F8) Liquids Lighter than aqueous Silicone oil Heavier than aqueous Perfluorocarbon liquids, Semiflourinated alkanes, Fluorinated silicone oil
  • 8. Experimental Vitreous substitutes4 a) Polymers • Hydrogels • Smart hydrogels • Thermosetting gels b) Implants c) Cell culture
  • 10. • 1911 by Ohm. • Rosengren used intravitreal air injection with drainage of subretinal fluid and diathermy • 1973, Norton used sulfur hexafluoride (SF6) gas for a longer tamponade >air used for difficult retinal detachments, particularly giant tears. • Lincoff and associates then developed several perfluorocarbon gases
  • 12. • SURFACE TENSION • BUOYANCY • SOLUBILITY • BIOCOMPATIBILITY
  • 13. • Surface tension – between gas bubbles and surrounding fluids critical physical property of the gases in retinal reattachment • Electrostatic attractive forces -van der Waals forces -weaker and longer range
  • 14. • Buoyancy-ability to float • Due to large difference in specific gravity of fluid and gas • superior tear tamponaded with a large air bubble • Displaces fluid inferiorly and away from the tear • Flattens against the wall of the eye.
  • 15. • Buoyancy directs the effectiveness of the tamponade, gases -upward gravitational direction. • Large bubbles and face- down positioning are required to tamponade inferior retinal breaks apposition of the gas bubble against the posterior pole and macula during face down positioning.
  • 16. • Solubility of a gas in the aqueous medium : determining the reabsorption rate of a gas bubble from the vitreous cavity • If less soluble than nitrogen, expansion of the bubble can occur
  • 17. Biocompatibility • SF6 and the perfluorocarbon gases have a purity of 99.8% • Pure gases -chemically nonreactive, colorless, odorless, and nontoxic • SF6 may -0.3 ppm of hydrogen fluoride. regarded as the most toxic contaminant found in SF6.
  • 18. • When bubble is large enough , covers the back of the lens, a cataract develops unless the patient is positioned so that a layer of fluid covers the posterior surface of the lens • On contact with corneal endothelium -causes increased inflammation, >SF6 than perfluoropropane • Persistent corneal edema and retro- corneal membrane - interference with nutrition of the endothelium rather than to a specific toxic effect
  • 20. • Bubble Expansion-gas from surrounding fluid enter the bubble • Equilibrium with N2: partial pressures of both compartments equilibrate: o2/co2 diffuse rapidly, N2 slowly, maximum in 6-8 hours • Bubble dissolution: as gases diffuse out bubble decreases in size
  • 21. Role of Gas bubble • Bubble larger than the break-surface tension of gas prevents it from passing through the retinal break • Gas bubble apposed to the posterior end of break • Passage of fluid from the vitreous to SRF blocked • SRF absorbed into RPE and choroid
  • 22. • Sp gravity of gas lower than water • Buoyant forces push retina against RPE (max at apex ) 10x > silicone oil) • Head position till chorio- retinal adhesion Advantages: • When visualisation of retina is difficult-optical window • Allows fluid gas exchange • Mechanical barrier-cellular elements & growth factors “compartmentalisation”
  • 23. 0.3-0.5ml injected rapidly into the eye to avoid “fish egg bubble “formation
  • 24. Factors affecting dissolution • Vitreous currents • Surface area of bubble • Gas solubility in fluid • Diffusion coefficient of gas • Partial pressures • Ocular blood flow
  • 26. CHANGES IN THE VITREOUS • In a non vitrectomised eye: collagen condensed and compacted behind lens and at optic nerve head • Hyaluronic acid expressed from vitreous space • Lamellae - concave margins and rolled edges • ? Formation of pre retinal membranes complicating retinal detachment
  • 27. Choice of Gas Condition Xenon Air SF6 C2F6 C3F8 RD 2 1 1 2 -- PDR -- 1 1 2 -- RD+mac hole -- 2 1 -- 2 GRT -- 1 1 -- 2 PVR -- -- -- -- 1 Trauma -- 2 1 1 2 1-mc used 2- selected cases
  • 28. • Inj using 30 g , 13 mm needle • Injected immediately
  • 29. • Head position during air fluid exchange
  • 30. Complications of gas use • Cataract or corneal opacity -Face-down or lateral positioning is necessary to prevent continuous contact of the gas bubble with the cornea and lens • Glaucoma -large bubble -if the patient remains supine, fluid from the ciliary body fills the posterior segment & air bubble blocks fluid egress through the trabecular meshwork -Medium size -peripheral anterior synechiae with total angle closure
  • 31. • Central Retinal Artery Occlusion -Overfilling of the eye with expansile gas • Laser treatment -undesirable burns -Reflections of internal fluid–air and air–fluid surfaces. -Avoid treatment through a gas–fluid or fluid–gas interface -Perpendicular to the interface: intensity of a reflected beam increases as the angle of incidence decreases. -A divergent beam should be used • Endophthalmitis
  • 32. • Subretinal gas • New tears -7% to 23% of patients treated with pneumatic retinopexy • Dislocated intraocular lens implant Gas injection into vitreous base accidentally A. Donut sign when gas encircles the lens posteriorly. B. B. Sausage sign when gas partially encircles the lens posteriorly. In both cases the gas bubble is immobile
  • 34. • Fluorine and carbon atoms - most biologically inert in the eye • Surface tension of approximately 14 to 16 dynes/cm measured against air –comparable to silicone oil • Most remarkable property of the perfluorocarbon liquids is the specific gravity, which is higher than that of water. • specific gravities range from 1.7 to 2.03
  • 35. • Enables the fluid to settle posteriorly, opening folds in the retina while expressing subretinal fluid anteriorly through pre- existing retinal breaks • Perfluorodecalin & perfluorophenanthrene -high transparency to light in the visible spectrum • No obstacle to laser photocoagulation • Perfluorooctylbromide is radiopaque, and it has potential application as a contrast agent
  • 36. Biocompatibility • Inferior corneal endothelial loss with subsequent corneal opacity and thickening • Dispersion and droplet formation will develop • Gial cell proliferation and retinal disorganization -1 month. • 3 months-preretinal membranes, gliosis, and retinal disorganization • 6 months, retinal detachments • Perfluorotributylamine -a “moth-eaten appearance,” - irregularly shaped defects in the outer segment discs in both the superior and the inferior retina after 2 days • Combined use of silicone oil and perfluoropolyether has shown a tendency to reduce the emulsification PFC
  • 37. 5 main indications: • Giant retinal tears • Detachments with complicated PVR • Traumatic retinal detachments • Removal of posterior lens fragments and posteriorly dislocated intraocular lenses • Macular rotation with a 360-degree retinotomy • +ROP
  • 38. • PVR: tamponade effect to open up funnel detachment exposing any areas of residual membranes • Giant retinal tears: unfolding and displacement of SRF and blood
  • 39. • PPV removal of anterior vitreous base • Crystalline lens floated anteriorly over ONH • SRF displaced through the break • Posterior retina flattened • Dislocated lens removed with fragmatome/vit cutter
  • 40. DISADVANTAGES • irreversible cell damage • Disorganization of retinal cell growth pattern, loss of neurites ADVANTAGES • Specific gravity of PFCLs - effective for the intraoperative repair of complex retinal tears • Anterior and posterior segment complications are uncommon • Low viscosity of PFCLs allow for tissue manipulation, injection, and removal
  • 42. • Semifluorinated alkanes (SFAs),or partially fluorinated alkanes (PFAs) or FA -first internal tamponade agents - used beyond the intraoperative setting • Low sp. gravity of SFA< PFCLs:so produce less retinal damage • Esp used for macular rotation surgery -press down on the retina less , allowing rotation of the unfolded macular without mechanical damage • Using F6H8 and OL62 HV oligomers increases viscosity and decreases droplet formation • Ex: Perfluorohexyloctane(F6H8/O68), Perfluorohexylethane(F6H2/O62) • Complications: Glaucoma-Superior PI, Cataract ,Droplet formation & dispersion
  • 44. • Silicone oil chains - helix with six silicium units per turn. • Pure 1,000-centistoke oil - helix of 63 turns and a 5,000-centistoke oil a helix of approximately 100 turns • Interdigitation of the helix & increasing molecular weight -viscosity linear chain coils into a helix, composed of 6 (Si-O) units per turn. For a molecular weight of 28,000 (1,000 centistokes), the helix will have 63 turns in average
  • 45. • Buoyancy: • Difference in specific gravity of aqueous humor, vitreous and hydrophobic polymer accounts for buoyancy • Force is spread over an area max at apex and decreases to zero at horizontal interface • Directs the tamponade of the immiscible silicone oil upward.
  • 46. Refractive state of the eye • Higher refractive index compared to vitreous • Refractive shift depends on lens status • Phakic eye-oil forms a concave surface behind lens Acts as a minus lens-making eye hyperopic-8D hyperopia • Aphakic eye-convex surface as it bulges through pupillary aperture-plus lens-myopic Varies with pupillary aperture size-from +12.5 to +5.6D • Contact lens –to minimise the anisoconia • IOL-plano posterior surface preferred
  • 49. B. Severe Proliferative Diabetic Retinopathy • Silicone oil: decreased post op hemorrhage • Rapid recovery • Especially in patients with anterior segment neovascularisation/anterior hyaloid proliferation • Acts by impending movement of vasoproliferative factors from posterior segment to anterior segment • PDR with rhegmatogenous RD involving the macula C. Macular Hole • RD due to macular hole • Idiopathic/Traumatic macular hole
  • 50. D. Giant Retinal Tears • Unfolding the tear • Long term tamponade E. Chronic uveitis with profound hypotony F. Infectious retinitis • RRD in CMV retinitis • Gancyclovir implants with silicone tamponade F. Endophthalmitis • Increase concentration of intravitreal antibioticcs • Antibacterial properties of silicone oil • Stabilise atrophic retina
  • 51. Complications of Silicone Oil • Cataract, • Glaucoma, • Keratopathy • Absorption of silicone oil by silicone intraocular lenses, • Migration of silicone oil into the optic nerve and rarely into the brain, and • Emulsification. • Retinopathy • Recurrent retinal detachments
  • 53. Emulsification of Silicone Oils • Smaller silicone oil droplets at the interface of oil droplet and intra ocular fluids • Factors promoting emulsification: -Difference in density of two liquids -Lower viscosity -Decrease in interfacial tension -Adsorption of surface active agents -Ocular saccadic motion (micro current in and outside the bubble) 1%-1month, 11%-3 months ,85% 6 months, 100%- 1 year 8
  • 55. • Choice of IOL: heparin coated PMMA/ regular PMMA • Silicone oil acts as a foreign substance and not reabsorbed by the eye • On removal-retinal redetachment 3-33% • Indications for removal: -Glaucoma -Keratopathy -reasonable chance that retina will remain attached (followed by infusion of BSS / Air –fluid exchange)
  • 57. • Disadvantages • can pass through retinal breaks under traction • Requires optical adjustments • tamponade of the inferior retina is difficult • Emulsification • Complications • Sticky silicone oil o Advantages • high surface tension, ease of removal, low toxicity, and transparency. • tamponade effect on the superior retina • airplane or high elevation travel is planned • post-operative positioning is difficult
  • 58. • Combinations “Double Fill” • Double fill (DF) is a combination of SO and SFAs, • light SO support the superior retina ,heavier SFA supports the inferior retina, • Tamponade agent and reduces dispersion “Heavy Silicone Oil” • SO and a PFA mixed in such a way as to create a homogenous solution. • More viscous, more stable • Complex retinal detachments involving inferior proliferative vitreoretinopathy • HSO can be challenging to remove-heavier than water
  • 60. vitreous molecular structure filling function, to control elasticity pressure of the eye chemical and physiological properties diffusion of metabolites and gases Perfusion of drugs Interact with intraocular structures
  • 61. A Natural Polymers • Hyaluronic acid (HA) and collagen, B Hydrogels “swell gels” • hydrophilic polymers that form a gel network when cross- linked & swell by absorbing several times their own weight in water • molecules as tamponades is coupled with the active action as drug releasers or exchangers
  • 62. • investigated include poly(vinyl alcohol),poly(1-vinyl-2- pyrrolidone), poly(acrylamide), copoly(acrylamide), polyvinyl alcohol methacrylate, poly(glyceryl methacrylate), poly(2- hydroxythylacrylate), and poly(methyl-2-acrylamido-2- methoxyacetate).
  • 63. C. Transplants & Implants • Transplant vitreal tissue • Correctly stored, the vitreous body :maintain its structure and also its enzymatic properties • Low inflammatory reaction and interesting surgical results on 40% of patients. • Cataract, glaucoma, and more severe adverse events until ocular atrophy .
  • 64. Implants • artificial capsular bodies, • silicone rubber elastomer and filled with a saline solution, • silicone oil, controlled using a valve system • FCVB • Good mechanical, optical, and biocompatible properties • PVA filling model • X. Lin, J. Ge, Q. Gao et al., “Evaluation of the flexibility, efficacy,and safety of a foldable capsular vitreous body in the treatment of severe retinal detachment,” Investigative Ophthalmology &Visual Science, vol. 52, no. 1, pp. 374–381, 2011.
  • 65. Future?? A. VITREOUS SUBSTITUTES AS A DRUG DELIVERY MEDIUM • A proper vitreous substitute used as a long-term (>3 months) drug delivery system to reduce or eliminate the need for multiple intra-vitreal injections • Hydrogels may be a promising biomaterial for fragile protein drug delivery B. CELL CULTURE/GENE THERAPY: CAN WE GROW VITREOUS?
  • 66. REFERENCES 1. SURVEY OF OPHTHALMOLOGY VOLUME 56 NUMBER 4 JULY–AUGUST 2011 Vitreous Substitutes: A Comprehensive Review Teri T. Kleinberg, MS, MD,1 Radouil T. Tzekov, MD, PhD,1 Linda Stein, MS,1 Nathan Ravi, MD, PhD,2 and Shalesh Kaushal, MD, PhD1 2. Duanes Ophthalmology Volume 6 ,Chapter 54 Vitreous Substitutes MARK E. HAMMER 3.Hindawi Publishing Corporation BioMed Research InternationalVolume 2014, Article ID 351804, 12 pagesReview Article Vitreous Substitutes: The Present and the Future Simone Donati,1 Simona Maria Caprani,1 Giulia Airaghi,1 Riccardo Vinciguerra,1 Luigi Bartalena,2 Francesco Testa,3 Cesare Mariotti,4 Giovanni Porta,5 Francesca Simonelli,3 and Claudio Azzolini1 4.Intraocular gas in vitreoretinal Surgery Shaheeda Mohamed, FRCS, Timothy Y. Y. Lai, MD, FRCS 5.Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong
  • 67. 5.Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong 6.Swartz M, Anderson DR: Use of Healon in posterior segment surgery. J Ocul Ther Surg , January-February, pp 26–28, 1984 7.Poole TA, Sudarsky RD: Suprachoroidal implantation for the treatment of retinal detachment. Ophthalmology 93:1408, 1986 8.Stenkula S, Ivert L, Gislason I, et al: The use of sodiumhyaluronate (Healon) in the treatment of retinal detachment. Ophthalmic Surg 12:435, 1981 9.Stenkula S: Sodium hyaluronate as a vitreous substitute and intravitreal surgical tool. In Rosen ES (ed): Viscoelastic Materials: Basic Science and Clinical Applications, pp 157–160. New York, Pergamon Press, 1989
  • 68. 10.Stephen J Ryan –Retina 4 th edition volume 3 11.Lincoff H, Mardirossian J, Lincoff A, et al: Intravitreal longevity of three perfluorocarbon gases. Arch Ophthalmol 98:1610, 1980 12.Silicone Study Group: Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: Results of a randomized clinical trial: Report 2 Arch Ophthalmol 110:780, 1992